Relapses in MS Patients Treated with DMF with no Variation in Lymphocyte Counts
Abstract
References
Nakhaei-Nejad, M., Barilla, D., Lee, CH., Blevins, G., Giuliani, F. (2018) Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod. Neurol Neuroimmunol Neuroinflamm, 5(2): e432.
Ruggieri, S., Tortorella, C., Gasperini, C. (2014) Pharmacology and clinical efficacy of dimethyl fumarate (BG-12) for treatment of relapsing-remitting multiple sclerosis. Ther Clin Risk Manag, 10: 229- 239.
Scannevin, RH., Chollate, S., Jung, MY., Shackett, M., Patel, H., Bista, P., et al. (2012) Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroidderived 2)-like 2 pathway. J Pharmacol Exp Ther, 341(1): 274-284.
Treumer, F., Zhu, K., Glaser, R., Mrowietz, U. (2003) Dimethylfumarate is a potent inducer of apoptosis in human T cells. J Invest Dermatol, 121(6): 1383-1388.
Chaves, C., Ganguly, R., Ceresia, C., Camac, A. (2017) Lymphocyte subtypes in relapsing-remitting multiple sclerosis patients treated with dimethyl fumarate. Mult Scler J Exp Transl Clin, 3(2): 2055217317702933.
Peng, H., Guerau-de-Arellano, M., Mehta, VB., Yang, Y., Huss, DH., Papenfuss, TL., et al. (2012) Dimethyl fumarate inhibits dendritic cell maturation via nuclear factor kappaB (NF-kappaB) and extracellular signal-regulated kinase 1 and 2 (ERK1/2) and mitogen stressactivated kinase 1 (MSK1) signaling. J Biol Chem, 287(33): 28017- 28026.
Fox, RJ., Miller, DH., Phillips, JT., Hutchinson, M., Havrdova, E., Kita, M., et al. (2012) Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med, 367(12): 1087-1097.
Gold, R., Kappos, L., Arnold, DL., Bar-Or, A., Giovannoni, G., Selmaj, K., et al. (2012) Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med, 367(12): 1098-1107.
Fox, RJ., Chan, A., Gold, R., Phillips, JT., Selmaj, K., Chang, I., et al. (2016) Characterizing absolute lymphocyte count profiles in dimethyl fumarate-treated patients with MS: Patient management considerations. Neurol Clin Pract, 6(3): 220-229.
Longbrake, EE., Naismith, RT., Parks, BJ., Wu, GF., Cross, AH. (2015) Dimethyl fumarate-associated lymphopenia: Risk factors and clinical significance. Mult Scler J Exp Transl Clin, 1.
